

Press release

Updated S3 guideline irritable bowel syndrome with new bacterial strain: *B. bifidum* MIMBb75, exclusively contained in *Kijimea*[®] Irritable Bowel Syndrome, has officially been included in the S3 guideline

Gräfelfing, 31.08.2021. A success for the patented bacterial strain of SYNformulas for the treatment of irritable bowel syndrome: The innovative bacterial strain *B. bifidum* MIMBb75, which is exclusively contained in *Kijimea*[®] IBS, has been included in the recently updated and published "S3 guideline on the definition, pathophysiology, diagnostics and therapy of irritable bowel syndrome". It is the only bacterial strain listed with significant effect on all leading symptoms such as diarrhoea, abdominal pain, flatulence and constipation. The product *Kijimea*[®] Irritable Bowel once again receives independent confirmation of its relevance in the therapy of irritable bowel syndrome. The bacterial strain *B. bifidum* MIMBb75 is exclusively contained in the product *Kijimea*[®] IBS and in heat-inactivated form in *Kijimea*[®] IBS PRO.

The aim of the first revision of the guideline adopted in 2010 is to compile the current state of knowledge on the still increasing clinical picture of irritable bowel syndrome, to evaluate new diagnostic and therapeutic options and to translate them into recommendations for clinical practice. The results serve as orientation in clinical practice and improve the outpatient and inpatient medical care of patients suffering from IBS. The S3 guideline is prepared with editorial independence and in a lead role by the DGVS, a German scientific expert association for digestive and metabolic diseases and the DGNM, the German association for neurogastroenterology and motility.

David Rietbrock, Managing Director of Synformulas GmbH: "We have set ourselves the goal to advance the treatment of common diseases such as the irritable bowel syndrome by recommending selected probiotics and further expanding the acceptance of clinically proven therapy options. The inclusion of the bacterial strain *B. bifidum* MIMBb75 in the S3 guideline therefore honours us greatly and is a clear sign that *Kijimea*[®] IBS is a highly relevant therapy option: our patented bacterial strain is the only strain mentioned that has a significant effect on all leading symptoms."

The bacterial strain *B. bifidum* MIMBb75 is used in the market-leading products *Kijimea*[®] IBS and *Kijimea*[®] IBS PRO and can significantly relieve the symptoms of IBS diarrhoea, abdominal pain, bloating and constipation. This has been proven in two independent gold standard studies. The effect of *Kijimea*[®] IBS PRO, which contains the heat-inactivated bacterial strain *B. bifidum* HI-MIMBb75, was most recently proven in a study³ with 443 subjects in April 2020, which was published in the medical journal *The Lancet Gastroenterology & Hepatology*.

Further information on the mode of action of *Kijimea*[®] IBS and *Kijimea*[®] IBS PRO: <https://www.kijimea.com/>

About SYNformulas GmbH

SYNformulas is a leading global probiotics company focused on researching the human microbiome and developing breakthrough, evidence-based probiotics that significantly improve the quality of lives. Under the brand Kijimea®, the company's medical products, nutritional supplements and products for supplementary balanced diets are sold on a pharmacy-exclusive basis.

SYNformulas achieved a breakthrough in the treatment of irritable bowel syndrome: In two independent studies the patented bacterial strain *B. bifidum* MIMBb75 showed significant efficacy and was most recently included in the S3 guideline Irritable Bowel Syndrome.

For future-oriented product development with clinically proven efficacy, the company based in Gräfelfing relies on an efficient research & development team as well as on cooperating with a broad network of internationally recognised researchers and universities. SYNformulas is a subsidiary of FUTRUE, the healthcare incubator, which operates internationally with over 20 companies.

www.synformulas.com

Press contact:

Annabella Martinz

E-Mail: press@SYNformulas.com